4

Name Harinath Reddy Bandlapalli

Age / Sex 33 years / Male
Contact 9885889499
Referral Doctor Self
This Section An abridged abstract. Not a Clinical Laboratory Report NABL Certificate: MC-6095

INVESTIGATION YOUR CURRENT VISIT FROM YOUR PREVIOUS 3 VISITSa

21-Jan-24 BRIb 16-Jul-23

Glucose - Fasting 101 70-100 115
Method: Hexokinase

Hemoglobin A1c 6.3 0-5.7 6.8

Method: HPLC

Triglycerides 118 0-150 222

Method: GPO POD

Cholesterol - Total 154 0-200 229

Method: Cholesterol Oxidase
Peroxidase

Cholesterol - HDL 44 40-60 39

Method: Enzymatic Immuno
Inhibition

Cholesterol - LDL 86 0-100 146

Method: Calculated

Creatinine - Serum 0.88 0.84-1.25 1.0

Method: Jaffe kinetic IDMS
Traceable

Bilirubin Total 0.80 0.3-1.2 -

Method: DPD Diazotization

Alanine Aminotransferase ( 29 0-50 -

ALT/SGPT)
Method: UV Kinetic IFCC without
P5P

Aspartate Aminotransferase 23 0-50 -

(AST/SGOT)
Method: UV Kinetic IFCC without
P5P

Alkaline Phosphatase (ALP) 70 30-120 -

Method: pNPP AMP Buffer IFCC

NOTES
a. From previous 3 visits in preceding 2 years. If your past results are not mentioned, please contact us at 040-6700 6700
b. BRI = Biological Reference Interval. Depending on the test / parameter, the BRI may differ on account of gender and age.
For the sake of brevity, the units have not been mentioned in this table. Please refer to the Clinical Laboratory Report for
details.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com
 4

Preliminary Assessment

Glucose-Fasting: You could benefit from analyzing and reworking your current diet. As a basic starting point,
whole grains are better than refined grains because they tend to be high in fiber and take longer to digest. This
will satisfy your hunger better and help lower blood glucose levels and reduce fat.
HbA1c: You should check for non-medication measures that help in reducing HbA1c. Monitor your HbA1c level 2
to 4 times a year; you might need more frequent testing if your physician modifies your treatment plan or if you
start a new medication.
Great news! Your Triglycerides test result falls within the acceptable range. In your body, triglycerides constitute
a common form of fat. Elevated triglyceride levels, however, can increase your vulnerability to conditions like
heart attacks and strokes.
We're glad to note that your Cholesterol-Total test result falls within the acceptable range. Your cholesterol
levels indicate the amount of cholesterol circulating in your bloodstream. To ensure optimal cholesterol levels,
strive for elevated levels of HDL (good cholesterol) and aim to keep your LDL (bad cholesterol) low.

Screening & Vaccination Recommendations

Grade A Colorectal Cancer, HIV, Hypertension

Grade-A: As categorized and recommended by the US Preventive Services Task Force.
There is high certainty that the net benefit is substantial
Alcohol Abuse (Alcohol Level Serum, GTT), Hepatitis C (Hepatitis C Virus-HCV Antibody
Annual ELISA), HIV (HIV 1 & 2 Antibody ELISA), Tobacco Use (Urine Cotinine Nicotine Test),
Hepatitis B (Hepatitis B Surface Antigen-HBsAg ELISA)
Hypertension (Hypertension Profile), Obesity (MDx Weight Watch Advanced),
Periodic: every 2y
USG-Liver, USG-Abdomen, X Ray-Chest, ECG, 2D Echo, BMD
Periodic: every 3y Diabetes (HbA1c), MRI-Brain, MRI-Spine, CT-Abdomen, CT-Chest
Colorectal Cancer (Colonoscopy, MSI Testing), Hyperlipidemia (Lipid Profile), Lung
Periodic: every 5y
Cancer
Hepatitis B, Human papillomavirus (HPV), Influenza, Tetanus, Diphtheria, Acellular
Vaccinations: Important
Pertussis (Tdap and Td)

Please consult a Registered Medical Practitioner for review and consultation, before
Important Disclaimer
proceeding on the above assessment and recommendations

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 07:35 PM
Referral Doctor Self Report Status Final

Vitamin D 25 Hydroxy
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

25 Hydroxy vitamin D 29.06 ng/mL 31-100

Method: CLIA

Interpretation of Vitamin D
Level Results(in ng/mL) Comments
Deficient < 20.0 High risk of developing bone disease.
Insufficient 21-30 Vitamin D concentration normalizes Parathyroid Hormone concentration
Sufficient 31-100 Optimal concentration for maximal benefit.
Potential intoxication > 100 High risk of toxic effects
Clnical Significance
a) Vitamin D is a fat soluable vitamin involved in the intestinal absorption of calcium and regulation of calcium metabolism
b) It plays a vital role in the formation and maintenance of strong , healthy bones.
c) Vitamin D deficiency has long been associated with rickets in children and osteomalacia in adults and long term insufficiency of
calcium and vitamin D leads to osteoporosis.
d) However , in recent years, vitamin D has become an assay of general health status , and there have been multiple publications linking
vitamin D deficiency to several disease states, such as cancer cardiovascular disease and autoimmune diseases.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 1 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Lipid Profile
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Cholesterol - Total 154 mg/dL 0-200

Method: Cholesterol Oxidase Peroxidase

Cholesterol - HDL 44 mg/dL 40-60

Method: Enzymatic Immuno Inhibition

Cholesterol - LDL 86 mg/dL 0-100

Method: Calculated

Cholesterol VLDL 24 mg/dL 5 - 40

Method: Calculated

Cholesterol Total/HDL Ratio 3.5 4-6

Method: Calculated

Cholesterol LDL/HDL Ratio 2.0 1.5 - 3.6

Method: Calculated

Triglycerides 118 mg/dL 0-150

Method: GPO POD

Interpretation of results
Risk Stratification Total Cholesterol LDL Cholesterol Non-HDL Cholesterol Triglyceride
Optimal <200 <100 <130 <150
Above Optimal 100-129 130-159 130-159
Borderline High 200-239 130-159 160-189 160-189
High >=240 160-189 190-219 190-219
Very high >=190 >=220 >=220

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020
Risk Groups Treatment Goals Consider Drug Therapy
LDL-C (mg/dL) Non-HDL (mg/dL) LDL-C (mg/dL) Non-HDL (mg/dL)
Extreme Risk Group Category A <50 (Optional goal ≤30) <80 (Optional goal ≤60) ≥50 ≥80
Extreme Risk Group Category B ≤30 ≤60 >30 >60
Very High Risk <50 <80 ≥50 ≥80
High Risk <70 <100 ≥70 ≥100
Moderate Risk <100 ≥100 ≥130
Low risk <100 ≥130* ≥160*
*After an adequate non-pharmacological intervention for at least 3 months

Clinical Significance
• Measurements in the same patient can show physiological and analytical variations. Three serial samples 1 week apart are

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 2 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Lipid Profile
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

recommended for Total cholesterol, Triglycerides , HDL & LDL Cholesterol.

• Friedewald equation to calculate LDL cholesterol is most accurate when triglyceride level is < 400mg/dL. Measurement
of Direct LDL Cholesterol is recommended when Triglyceride level is >400 mg/dL.
• Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for Atherosclerotic Cardiovascular
Disease (ASCVD) risk factors, especially lipid profile. This should be done earlier if there is a family history of premature heart
disease, dyslipidemia, obesity, or other risk factors.
• Lipid association of India recommends LDL-C as the primary target and non-HDL-C as a co-primary target, for lipid-lowering therapy.
• Non-HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL, VLDL & VLDL remnants,
Chylomicron remnants and Lp(a).
• Apo B measurement is recommended in high-risk subjects after LDL-C and non-HDL-C goals have been achieved.
• Additional testing for Apolipoprotein B, hsCRP, Lp(a ) and LP-PLA2 should be considered among patients with moderate risk
for ASCVD for risk refinement.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 3 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Kidney Profile I
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Urea 27 mg/dL 17-43

Method: GLDH Kinetic

Clinical Significance: Urea

• Serum urea and serum creatinine determinations are frequently performed together in the differential diagnosis of kidney function.
• Plasma urea concentration is determined by renal perfusion, urea synthesis rate, and glomerular filtration rate (GFR) and may be
increased in acute renal failure, chronic renal failure and prerenal azotaemia.
• Prerenal elevation of urea occurs in cardiac decompensation, increased protein catabolism and water depletion.
• Urea levels may be elevated due to renal causes such as acute glomerulonephritis, chronic nephritis, polycystic kidney, tubular necrosis
and nephrosclerosis.
• Post renal elevation of urea may be caused by obstruction of the urinary tract.
• In dialysis patients the urea concentration is representative of protein degradation and is also an indicator of metabolic status.
• In end-stage renal failure, the urotoxic signs, relating to the gastrointestinal system, correlate well with urea concentration.

Creatinine - Serum 0.88 mg/dL 0.84-1.25

Method: Jaffe kinetic IDMS Traceable

Clinical Significance: Creatinine

• Measurements of creatinine are used in the diagnosis and treatment of renal disease and prove useful in the evaluation of kidney
glomerular function and in monitoring renal dialysis.
• Serum level is not sensitive to early renal damage and responds more slowly than blood urea nitrogen (BUN) to haemodialysis during
treatment of renal failure.
• Both serum creatinine and BUN are used to differentiate prerenal and postrenal (obstructive) azotemia.
• An increase in serum BUN without concomitant increase of serum creatinine is key to identifying prerenal azotemia.
• In post renal conditions where obstruction to the flow of urine is present e.g. malignancy, nephrolithiasis and prostatism, both the plasma
creatinine and urea levels will be increased; in these situations the rise is disproportionately greater for BUN

Uric Acid 5.6 mg/dL 3.5-7.2

Method: Uricase POD

Clinical Significance: Uric acid

• Primary hyperuricaemia is associated with gout, Lesch-Nyhan syndrome, Kelley Seegmiller syndrome and increased phosphoribosyl
pyrophosphate synthase activity.
• Secondary hyperuricaemia is associated with numerous conditions including renal insufficiency, myeloproliferative diseases, haemolytic
diseases, psoriasis, polycythemia vera, type I glycogen storage disease, excess alcohol consumption, lead intoxication, a purine-rich diet,
fasting, starvation and chemotherapy.
• Hypouricaemia may also be due to increased renal uric acid excretion, which may occur in malignant diseases, AIDS, Fanconi syndrome,
diabetes mellitus, severe burns and hypereosinophilic syndrome.
• Quantitation of urinary uric acid excretion may assist in the selection of appropriate treatment for hyperuricaemia, providing an indication
of whether patients should be treated with uricosuric drugs to enhance renal excretion, or allopurinol to supress purine synthesis.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 4 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Kidney Profile I
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Urea/Creatinine Ratio 30.7 Ratio

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 5 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 07:36 PM
Referral Doctor Self Report Status Final

Thyroid Profile
Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

TT3 (Tri-Iodothyronine Total) 102.10 ng/dL 60-181

Method: CLIA

Clinical Significance: T3
• Diagnostically, T3 concentration is more sensitive to certain thyroid conditions than T4.
• T4 levels are a sensitive (and superior) indicator of hypothyroidism, T3 blood levels better define hyperthyroidism.
• Because T3 concentration in serum changes faster and more markedly than T4, the T3 level is also an excellent indicator of the ability of
the thyroid to respond to both stimulatory and suppressive tests.
• Under conditions of strong thyroid stimulation, the T3 level offers a good estimation of thyroidal reserve as well.

TT4 (Thyroxine - Total) 9.8 µg/dL 4.5-10.9

Method: CLIA

Clinical Significance: T4
• Thyroxine (T4) is a hormone synthesized and secreted by the thyroid gland, and plays an important role in regulating metabolism.
• Primary malfunction of the thyroid gland may result in excessive (hyper) or below normal (hypo) release of T4 or T3.
• Thyroid function is directly affected by TSH and malfunction of the pituitary or the hypothalamus influences the thyroid gland activity.
• Disease in any portion of the thyroid-pituitary-hypothalamus system may influence the levels of T4 and T3 in the blood.

TSH-Ultrasensitive 4.303 µIU/mL 0.55 - 4.78

Method: CLIA

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 6 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Liver Function Test (LFT)

Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Bilirubin Total 0.80 mg/dL 0.3-1.2

Method: DPD Diazotization

Bilirubin Direct 0.16 mg/dL 0.0-0.20

Method: DPD Diazotization

Bilirubin Indirect 0.64 mg/dL 0 - 0.8

Method: Calculated

Clinical Significance : Total Bilirubin

• Prehepatic Jaundice : Diseases of prehepatic origin with predominantly unconjugated hyperbilirubinemia
a) Corpuscular haemolytic anemias e.g. thalassemia and sickle cell anemia;
b) Extracorpuscular haemolytic anemia e.g. blood transfusion reaction due to ABO and Rh incompatibility;
c) Neonatal jaundice and haemolytic disease of the newborn.
• Hepatic Jaundice : Diseases of hepatic origin with predominantly conjugated hyperbilirubinemia include acute and chronic viral hepatitis,
liver cirrhosis and hepatocellular carcinoma.
• Post hepatic Jaundice: Diseases of post-hepatic origin with predominantly conjugated hyperbilirubinemia include extrahepatic cholestasis
and liver transplant rejection.
• Chronic congenital hyperbilirubinemias include the unconjugated hyperbilirubinemias Crigler-Najjar syndrome and Gilbert's syndrome
as well as the conjugated hyperbilirubinemias Dubin-Johnson syndrome and Rotor syndrome.

Clinical Significance : Direct Bilirubin

• The assessment of direct bilirubin is helpful in the determination of hepatic and post-hepatic jaundice.

Alanine Aminotransferase (ALT/SGPT) 29 IU/L 0-50

Method: UV Kinetic IFCC without P5P

Clinical Significance : Alanine Aminotransferase (ALT)

• Elevated serum ALT activity is mainly regarded as an indicator of parenchymal liver disease.
• Increased serum levels indicate deterioration in the integrity of the hepatocyte plasma membrane.
• ALT has greater diagnostic sensitivity for hepatobiliary disease than AST.
• Activities >50 times the upper reference limit are mainly associated with acute viral hepatitis, acute disorders of liver perfusion and
acute liver necrosis due to ingestion of toxins including paracetamol and carbon tetrachloride.
• Markedly elevated serum ALT levels is found in hepatitis, mononucleosis and cirrhosis.
• Levels greater than 15 times the upper reference limit are indicative of acute hepatocellular necrosis of viral, toxic or circulatory origin.

Aspartate Aminotransferase (AST/SGOT) 23 IU/L 0-50

Method: UV Kinetic IFCC without P5P

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 7 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Liver Function Test (LFT)

Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Clinical Significance : Aspartate Aminotransferase (AST)

• Measurement of AST is indicated in the diagnosis, differentiation and monitoring of hepatobiliary disease, myocardial infarction and
skeletal muscle damage.
• AST levels may be increased in viral hepatitis and liver disease associated with hepatic necrosis, with 20 to 50 fold elevations frequently
encountered.
• The evaluation of AST activity in relation to ALT (De Ritis ratio; AST/ALT) is a useful indicator of liver damage.
• Ratios > 1.0 are indicative of severe liver disease, usually involving necrosis.
• Ratios < 1.0 are indicative of mild liver damage associated with inflammatory conditions.

Alkaline Phosphatase (ALP) 70 IU/L 30-120

Method: pNPP AMP Buffer IFCC

Clinical Significance : Alkaline Phosphatase (ALP)

• Increases in total ALP are either due to physiological causes, or are caused by diseases of the liver or bone.
• Physiological increases in ALP are found in pregnancy from the 2nd trimester onwards due to placental ALP, in growing children due to
bone ALP and postprandially in individuals with blood groups B and O, who are secretors of blood group substance H (intestinal ALP).
• Most common cause of elevated ALP is hepatobiliary disease.
• Primary bone diseases with elevated ALP : osteomalacia, osteogenesis imperfecta, vitamin D intoxication and primary bone tumours.
• Secondary bone diseases with elevated ALP : skeletal metastases, and in diseases such as multiple myeloma, acromegaly, renal
insufficiency, hyperthyroidism, ectopic ossification, sarcoidosis, bone tuberculosis and healing fractures.

Protein - Serum 7.2 gm/dL 6.6-8.3

Method: Biuret Serum blank End point

Albumin-serum 4.3 gm/dL 3.5-5.2

Method: Bromocresol Green

Globulin-Serum 2.9 gm/dL 2.2 - 4

Method: Calculated

Albumin/Globulin Ratio 1.5 1.2-2.5

Method: Calculated

Clinical Significance : Albumin

• Measurements of albumin concentrations are vital to the understanding and interpretation of calcium and magnesium levels
because these ions are bound to albumin, and decreases of albumin are directly responsible for depression of their concentrations.
• Hyperalbuminemia is infrequent and is caused by severe dehydration and excessive venous stasis.
• Hypoalbuminemia due to impaired synthesis : Liver disease or in protein deficient diets.
• Hypoalbuminemia due to increased catabolism : Tissue damage and inflammation
• Hypoalbuminemia due to reduced absorption of amino acids : Malabsorption syndromes or malnutrition.
• Hypoalbuminemia due to protein loss : Nephrotic syndrome, enteropathy or burns.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 8 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Liver Function Test (LFT)

Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 9 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 02:44 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 05:15 PM
Referral Doctor Self Report Status Final

Creatinine, Serum
MDx Diabetes Basic Department of Clinical Biochemistry
SampleType: Serum

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Creatinine - Serum 0.88 mg/dL 0.84-1.25

Method: Jaffe kinetic IDMS Traceable

Clinical Significance: Creatinine

• Measurements of creatinine are used in the diagnosis and treatment of renal disease and prove useful in the evaluation of kidney
glomerular function and in monitoring renal dialysis.
• Serum level is not sensitive to early renal damage and responds more slowly than blood urea nitrogen (BUN) to haemodialysis during
treatment of renal failure.
• Both serum creatinine and BUN are used to differentiate prerenal and postrenal (obstructive) azotemia.
• An increase in serum BUN without concomitant increase of serum creatinine is key to identifying prerenal azotemia.
• In post renal conditions where obstruction to the flow of urine is present e.g. malignancy, nephrolithiasis and prostatism, both the plasma
creatinine and urea levels will be increased; in these situations the rise is disproportionately greater for BUN

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 10 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 01:48 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 03:02 PM
Referral Doctor Self Report Status Final

Blood Glucose, Fasting

MDx Diabetes Basic Department of Clinical Biochemistry
SampleType: FASTING SODIUM FLUORIDE PLASMA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Glucose - Fasting 101 mg/dL 70-100

Method: Hexokinase

Criteria for the diagnosis of diabetes

a) Fasting Plasma Glucose >=126 mg/dL (7.0 mmol/L).
or
b) Hemoglobin A1C >=6.5% (48 mmol/mol).
or
c) In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >=200 mg/dL (11.1 mmol/L).
Note:
*In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate
test samples

Criteria defining prediabetes*

a) Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG).
or
b) Hemoglobin A1C 5.7–6.4% (39–47 mmol/mol).
Note:
*For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the
higher end of the range.

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 11 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 01:28 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 06:10 PM
Referral Doctor Self Report Status Final

Hemoglobin A1c
MDx Diabetes Basic Department of Clinical Biochemistry
SampleType: Whole Blood EDTA

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Hemoglobin A1c 6.3 % 0-5.7

Method: HPLC

Estimated Average Glucose(eAG) 134 mg/dL

Method: Calculated

Interpretation of Results
Result (%) Interpretation
< 5.7 (<39 mmol/mol) : Normal
5.7 - 6.4 (39-47 mmol/mol) : Prediabetes
>=6.5 (48 mmol/mol) : Diabetes
Glycemic Control in Diabetic Patients
Result (%) Interpretation
< 7.0 Good control
7.0 -8.0 Inadequate control
> 8.0 Poor control
Note:
• Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the HbA1C
result does not correlate with the patient’s blood glucose levels.
• Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD
or advanced microvascular complications, hypoglycaemia unawareness and individual patient considerations.

Clinical significance
• This test is diagnostic in a patient with classic symptoms of hyperglycemia or Hyperglycemic crisis.
• HbA1c is used for monitoring diabetic control. It reflects the mean plasma glucose over 8-12 weeks.
• Trends in HbA1c are a better indicator of diabetic control than a solitary test.
• Any sample with >15% HbA1c should be suspected of having a hemoglobin variant, especially in a non-diabetic patient.
• Results below 4% should prompt additional studies to determine the possible presence of variant hemoglobin.
• Values may not be comparable with different methodologies and even different laboratories using same methodology.
• HbA1c target in pregnancy is to attain level <6 % .
Reference : American Diabetes Association (ADA) - Standards of Medical Care in Diabetes 2022

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 12 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 01:28 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 06:10 PM
Referral Doctor Self Report Status Final

Hemoglobin A1c
MDx Diabetes Basic Department of Clinical Biochemistry
SampleType: Whole Blood EDTA

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 13 of 15
Name Harinath Reddy Bandlapalli Order PTGOR2300046777
Age / Sex 33 years / Male Sample Drawn 22-Jan-24 / 08:55 AM
Contact 9885889499 Sample Accepted 22-Jan-24 / 12:28 PM
Collection Centre INTGHYD95240 Sample Reported 22-Jan-24 / 06:10 PM
Referral Doctor Self Report Status Final

Microalbumin / Creatinine Ratio, Urine

MDx Diabetes Basic Department of Clinical Biochemistry
SampleType: URINE

INVESTIGATION RESULT UNITS BIOLOGICAL REFERENCE INTERVAL

Microalbumin - Spot Urine 1.1 mg/dL 0-30

Method: Immuno turbidimetry

Creatinine - Spot Urine 213.20 mg/dL 22 - 328

Method: Jaffe kinetic IDMS Traceable

Albumin Creatinine Ratio (ACR) 5.16 mg/gm < 30

Interpretation:
Category ACR (in mg/g) Description
A1 < 30 Normal to Mildly increased.
A2 30-300 Moderately increased.
A3 > 300 Severly increased.

*Categorization of Albuminuria based on Albumin-Creatine Ratio (ACR)

Clinical Significance:
a) ACR test is used to detect early kidney disease in those with diabetes or other risk factors such as high blood pressure (hypertension).
b) Albumin is a type of protein in blood, and when kidneys are functioning properly, virtually no albumin is present in the urine.
c) Creatinine is a byproduct of muscle metabolism and is normally released into the urine at a constant rate and its level in the urine is an
indication of urine concentration.
d) Albumin/creatinine ratio gives a more accurate indication of how much albumin is being released into the urine as compared to a spot
microalbumin test.

*** END OF THE REPORT ***

M Nageshwar Rao Dr G Srinivas Mr K Siddaiah M Jagannath

Verified by Director - Lab Services Verified by Verified by

Note: Please contact us for possible remedial action if test results are unexpected. Abnormal * Critical

MedPlus Health Services Limited #11-6-56, Opp: IDPL Railway Siding Road, Kukatpally, Hyderabad-500037, Telangana
CIN: U85110TG2006PLC051845 040 6700 6700 wecare@medplusmart.com www.medplusmart.com Page 14 of 15
Page 15 of 15